Summary
The kinetics and binding parameters of ceftriaxone have been characterized in eight normal subjects who received, in sequence, 1.0 g ceftriaxone and 1.0 g ceftriaxone together with 250 and 500 mg probenecid q.i.d.
Probenecid increased the total systemic clearance (CL TS ) from 0.244 to 0.312 ml/min/kg, whereas the terminal half-life (t T1/2(β) ) fell from 8.1 to 6.5 h. In contrast, the renal clearance of free ceftriaxone (CL FR ) was decreased from 2.09 to 1.67 ml/min/kg, confirming a small but significant contribution of tubular secretion to the renal elimination of ceftriaxone.
The final value of CL FR was attained with the lower dose probenecid, whereas the non-renal clearance of free ceftriaxone (CL FNR ) fell progressively from 2.78 to 1.90 ml/min/kg with the increasing probenecid dose. The total decrease in the systemic clearance of free ceftriaxone (CL FS ) after the higher dose of probenecid was about 30% (4.87 to 3.57 ml/min/kg).
As a consequence of a decreased affinity constant (KA), the average free fraction in plasma (f) was increased by 54% after the low dose and by 74% after the high dose of probenecid.
The protein binding interaction between probenecid and ceftriaxone appears to be unique. The results are of limited clinical consequence for ceftriaxone but they emphasise the importance of evaluating the kinetics of the free drug when examining interactions involving probenecid.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- AUCT, AUCF :
-
plasma AUC of total and free (unbound) drug
- CL TS , CL FS :
-
clearance: total systemic, free systemic
- CL TO , CL FR :
-
total oral, free renal
- CL FNR :
-
free non-renal
- V TZ V TSS :
-
apparent volume of distribution: terminal phase, total drug; corrected steady-state, total drug [14]
- f:
-
average free fraction of drug in plasma
- fe :
-
fraction of dose excreted unchanged in urine
- t T1/2(β) :
-
terminal t1/2: total drug
- t F1/2(β) :
-
free drug
- KA :
-
affinity constant
- nP:
-
capacity constant
- C ssav :
-
steady-state concentration in plasma during multiple dosing
- CB :
-
bound concentration
- CF :
-
free (unbound) concentration
References
Reiner R (1982) Antibiotics. Thieme, Stuttgart, New York
Angehrn P, Probst PJ, Reiner R, Then RL (1980) Ro 13-9904, a long-acting broad-spectrum cephalosporin: In vitro and in vivo studies. Antimicrob Agents Chemother 18: 913–921
Hayton WL, Schandalik R, Stoeckel K (1986) Biliary excretion and pharmacokinetics of ceftriaxone after cholecystectomy. Eur J Clin Pharmacol 30: 445–451
Stoeckel K, McNamara PJ, Brandt R, Plozza-Nottebrock H, Ziegler WH (1981) Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics. Clin Pharmacol Ther 29: 650–657
Patel IH, Chen S, Parsonnet M, Hackman MR, Brooks MA, Konikoff J, Kaplan SA (1981) Pharmacokinetics of ceftriaxone in humans. Antimicrob Agents Chemother 20: 634–641
Hayton WL, Stoeckel K (1986) Age-associated changes in ceftriaxone pharmacokinetics. Clin Pharmacokinet 11: 76–86
McNamara PJ, Stoeckel K, Ziegler WH (1982) Pharmacokinetics of ceftriaxone following intravenous administration of a 3-g dose. Eur J Clin Pharmacol 22: 71–75
Cunningham RF, Israili ZH, Dayton PG (1981) Clinical pharmacokinetics of probenecid. Clin Pharmacokinet 6: 135–151
Stoeckel K (1981) Pharmacokinetics of Rocephin, a highly active new cephalosporin with an exceptionally long biological half-life. Chemotherapy 27 [Suppl 1]: 42–46
Stoeckel K, McNamara PJ, Hoppe-Seyler G, Blumberg A, Keller E (1983) Single-dose ceftriaxone kinetics in functionally anephric patients. Clin Pharmacol Ther 33: 633–641
Scatchard G (1949) The attraction of protein for small molecules and ions. Ann NY Acad Sci 51: 660–672
Trautmann KH, Haefelfinger P (1981) Determination of the cephalosporin, Ro 13-9904 in plasma, urine and bile by means of ion-pair reversed phase chromatography. J High Resol Chromatogr Commun 4: 54–59
McNamara PJ, Gibaldi M, Stoeckel K (1983) Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. I Theoretical considerations. Eur J Clin Pharmacol 25: 399–405
Coffey JJ, Bullock FJ, Schoenemann PT (1971) Numerical solution of nonlinear pharmacokinetic equations: Effect of plasma protein binding on drug distribution and elimination. J Pharm Sci 60: 1623–1628
Sachs L (1984) Applied statistics. Springer, Berlin Heidelberg New York, p 549
Kates RE, Tozer TN (1976) Biliary secretion of methotrexate in rats and its inhibition by probenecid. J Pharm Sci 65: 1348–1352
Kenwright S, Levi AJ (1973) Impairment of hepatic uptake of rifamycin antibiotics by probenecid and its therapeutic implications. Lancet 2: 1401–1405
Baber N, Halliday L, Sibeon R, Littler T, Orme MLE (1978) The interaction between indomethacin and probenecid. Clin Pharmacol Ther 24: 298–307
Selen A, Amidon GL, Welling PG (1982) Pharmacokinetics of probenecid following oral doses to human volunteers. J Pharm Sci 71: 1238–1242
Paxton JW (1984) Interaction of probenecid with the protein binding of methotrexate. Pharmacology 28: 86–89
Sjöholm I, Ekman B, Kober A, Ljungstedt-Påhlman I, Seiving B, Sjödin T (1979) Binding of drugs to human serum albumin: XI. The specificity of three binding sites as studied with albumin immobilized in microparticles. Mol Pharmacol 16: 767–777
Sakamoto H, Murakawa T, Hirose T, Nishida M (1983) Effect of ceftizoxime, a new cephalosporin antibiotic, on binding of bilirubin to human serum albumin. Chemotherapy 29: 244–248
Gulian JM, Dalmasso C, Pontier F, Gonard V (1986) Displacement effect of ceftriaxone on bilirubin bound to human serum albumin. Chemotherapy 32: 399–403
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stoeckel, K., Trueb, V., Dubach, U.C. et al. Effect of probenecid on the elimination and protein binding of ceftriaxone. Eur J Clin Pharmacol 34, 151–156 (1988). https://doi.org/10.1007/BF00614552
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00614552